Clinical characteristics of the patients
| . | CHOP (128 patients) . | Rituximab (79 patients) . |
|---|---|---|
| Median age, y (range) | 51 (28-66) | 50 (28-66) |
| Aged over 60 y | 15 | 9 |
| Sex, male | 78 | 48 |
| Type of BCL2/IgH rearrangement | ||
| MBR | 115 | 71 |
| mcr | 13 | 8 |
| Disease stage at diagnosis | ||
| I | 1 | 0 |
| II | 12 | 4 |
| III | 26 | 16 |
| IV | 89 | 59 |
| Bone marrow involvement | 87 | 58 |
| Extranodal sites (other than BM) | ||
| 1 | 23 | 11 |
| 2 or more | 6 | 6 |
| PS more than 2 | 0 | 0 |
| B symptoms | 13 | 8 |
| Bulky disease* | 29 | 23 |
| Serum LDH | ||
| Normal | 106 | 67 |
| Elevated | 17 | 11 |
| Unknown | 5 | 1 |
| IPI | ||
| 0 to 1 | 82 | 49 |
| At least 2 | 37 | 29 |
| Unknown | 9 | 1 |
| Response to CHOP chemotherapy | ||
| CR | 73 | 39 |
| PR | 47 | 40 |
| NR | 8 | 0 |
| . | CHOP (128 patients) . | Rituximab (79 patients) . |
|---|---|---|
| Median age, y (range) | 51 (28-66) | 50 (28-66) |
| Aged over 60 y | 15 | 9 |
| Sex, male | 78 | 48 |
| Type of BCL2/IgH rearrangement | ||
| MBR | 115 | 71 |
| mcr | 13 | 8 |
| Disease stage at diagnosis | ||
| I | 1 | 0 |
| II | 12 | 4 |
| III | 26 | 16 |
| IV | 89 | 59 |
| Bone marrow involvement | 87 | 58 |
| Extranodal sites (other than BM) | ||
| 1 | 23 | 11 |
| 2 or more | 6 | 6 |
| PS more than 2 | 0 | 0 |
| B symptoms | 13 | 8 |
| Bulky disease* | 29 | 23 |
| Serum LDH | ||
| Normal | 106 | 67 |
| Elevated | 17 | 11 |
| Unknown | 5 | 1 |
| IPI | ||
| 0 to 1 | 82 | 49 |
| At least 2 | 37 | 29 |
| Unknown | 9 | 1 |
| Response to CHOP chemotherapy | ||
| CR | 73 | 39 |
| PR | 47 | 40 |
| NR | 8 | 0 |
Mass (> 10 cm) in one location or mediastinal mass (> 1/3 of the thoracic diameter).
MBR indicates major breakpoint region; mcr, minor cluster region; BM, bone marrow; PS, performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; and NR, nonresponsive.